

State of Delaware Group Health Insurance

FY 2018, 4th Quarter
Net Payments, Utilization and Trends from Incurred Claims

DRAFT



Notable Trends

For the current incurred rolling year period (July 1, 2017 – June 30, 2018) compared to the prior incurred rolling year period (July 1, 2016 – June 30, 2017) ¹:

- On a per member per month basis (PMPM) basis net medical and Rx payments increased from \$526 to \$537 (2.1%).
- Total net payments for medical and drug claims increased by 6.6% to over \$691.7 million. The increase was driven by a \$24.6 million (6.2%) increase in medical payments that included an \$13.9 million (13.7%) increase in medical payments among high cost claimants (HCCs). Net payments for chemotherapy among HCCs increased by \$6.6 million or 160 percent. There was also a sizeable increase (31.8%) in drug spending among HCCs.
- A large portion of the increase in the medical payments trend was attributable to outpatient facility claims (an increase of \$23.9 million and a 17.7% trend). Facility payments for outpatient specialty drugs increased by \$8.7 million (53.2%). Outpatient surgery payments increased by \$6.3 million (10.3%). Emergency room payments increased by \$4.5 million (11.6%).
- Payments for inpatient facility claims decreased by 3.4% from \$169 PEPM to \$163 PEPM driven largely by a decrease in utilization of surgical services (16%). Payments for facility claims for inpatient maternity increased by 18.3% despite a 12% decrease in utilization.
- Musculoskeletal conditions including osteoarthritis, arthropathies and joint disorders and spinal and back disorders continued to be among the top clinical conditions in terms of total net payments. Other top clinical conditions in terms of net payments included pregnancy related conditions and chemotherapy encounters.
- Utilization of urgent care facilities increased by 3.4% (from 454.9 visits per 1,000 to 470.3 visits per 1,000). Utilization of emergency rooms for services that could be provided in an urgent care setting decreased by 5.6 percent. PEPM payments for these visits increased by 8.8 percent.
- Utilization of high-tech radiology decreased at outpatient hospital facilities by 2.9 percent. However, payments increased from \$19 PEPM to \$23 PEPM at these facilities.
- Total net payments for specialty drugs increased by 23.9% contributing to an overall trend of 5.9% per employee per month (PEPM) for prescription drugs.

¹Report covers Delaware payroll groups which include Merit Employees, Merit Retirees, Medicare Retirees, Public Education and Higher Education. Participating groups and the University of Delaware are excluded. Reported payment totals, PMPM and PEPM include a completion factor that estimates payments beyond the three months runout period for incurred claims.

Net Payments Summary & Top Clinical Conditions

Total Net Payments

	Jul 2016 - Jun 2017	Jul 2017 - Jun 2018	Trend
Total Medical and Rx	\$649,131,270.71	\$691,724,509.27	6.6%
Total Medical and Rx PMPM	\$526	\$537	2.1%

Medical and Rx Net Payments for Members and High Cost Claimants²


	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
	Net Pay Med	Net Pay Rx	Net Pay Med	Net Pay Rx	Net Pay Med	Net Pay Rx
All Members	\$445,562,090	\$203,564,649	\$473,166,291	\$218,518,577	6.2%	7.3%
HCCs	\$101,973,267	\$24,423,138	\$115,896,625	\$32,182,206	13.7%	31.8%
Members excluding HCCs	\$343,588,823	\$179,141,510	\$357,269,666	\$186,336,371	4.0%	4.0%



Top Clinical Conditions by Net Payments



Jul 2016 - Jun 2017		Jul 2017 - Jun 2018	
Clinical Condition	Net Pay Med	Clinical Condition	Net Pay Med
Prevent/Admin Hlth Encounters	\$21,818,694	Prevent/Admin Hlth Encounters	\$22,751,990
Signs/Symptoms/Oth Cond, NEC	\$18,155,708	Signs/Symptoms/Oth Cond, NEC	\$20,704,016
Osteoarthritis	\$15,837,719	Osteoarthritis	\$15,246,330
Pregnancy without Delivery	\$14,670,964	Pregnancy without Delivery	\$15,243,321
Spinal/Back Disord, Low Back	\$13,543,403	Spinal/Back Disord, Low Back	\$13,206,471
Gastroint Disord, NEC	\$13,109,405	Arthropathies/Joint Disord NEC	\$12,951,721
Arthropathies/Joint Disord NEC	\$11,936,457	Chemotherapy Encounters	\$12,510,118
Respiratory Disord, NEC	\$9,884,240	Gastroint Disord, NEC	\$12,121,593
Coronary Artery Disease	\$9,545,688	Coronary Artery Disease	\$10,476,949
Cardiac Arrhythmias	\$7,943,153	Respiratory Disord, NEC	\$10,189,289



² High Cost Claimants (HCCs) are claimants with over \$100,000 total claims for the respective time periods.



Net Pay Per Employee Per Month (PEPM) and Utilization Trends by Service Category for Last 12 Quarters















Service Category Net Pay Summary

Net Payments Trends for Service Category Groups

Service Category Group	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend PEPM
	Net Pay Med	Net Pay PEPM Med	Net Pay Med	Net Pay PEPM Med	
Facility Outpatient	\$121,408,359	\$168	\$145,316,700	\$198	17.7%
Facility Inpatient	\$122,345,393	\$169	\$120,192,355	\$163	-3.4%
Physician Outpatient	\$65,113,384	\$90	\$66,227,433	\$90	0.0%
Other Professional Services	\$66,002,535	\$91	\$65,693,365	\$89	-2.1%
Radiology Outpatient	\$25,379,258	\$35	\$30,581,998	\$42	18.5%
MHSA	\$16,531,116	\$23	\$16,054,044	\$22	-4.5%
Physician Inpatient	\$17,445,376	\$24	\$15,742,769	\$21	-11.2%
Laboratory Outpatient	\$11,336,669	\$16	\$13,357,626	\$18	15.9%

Service Category Detail by Net Payments and Utilization

Facility Inpatient

Facility Inpatient Service Category	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Days per 1000	Net Pay Med	PEPM Med	Days per 1000	Net Pay Med	PEPM Med	Utilization	PEPM
Facility Inpatient Surgical	157.0	\$65,597,981	\$91	131.9	\$59,576,318	\$81	-16.0%	-10.7%
Facility Inpatient Medical	220.7	\$37,110,196	\$51	208.5	\$38,051,960	\$52	-5.5%	0.8%
Facility Inpatient Maternity	46.9	\$15,347,705	\$21	41.2	\$18,456,479	\$25	-12.0%	18.3%
Facility Inpatient Long Term Care		\$4,216,043	\$6		\$4,040,993	\$5		-5.7%
Facility Inpatient Non Acute		\$73,469	\$0		\$66,605	\$0		-10.8%

Facility Outpatient

Facility Outpatient Service Category	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Services per 1000	Net Pay Med	PEPM Med	Services per 1000	Net Pay Med	PEPM Med	Utilization	PEPM
Facility Outpatient Surgery	1,531.8	\$52,231,389	\$72	1,724.3	\$58,592,745	\$80	12.6%	10.3%
Facility Outpatient ER	2,185.0	\$33,379,392	\$46	2,282.8	\$37,888,525	\$52	4.5%	11.6%
Facility Outpatient Specialty Drugs	137.5	\$15,765,952	\$22	177.1	\$24,557,241	\$33	28.8%	53.2%
Facility Outpatient Diagnostic Services	207.0	\$6,756,592	\$9	212.5	\$8,155,382	\$11	2.6%	18.7%
Facility Outpatient Dialysis	319.3	\$5,239,680	\$7	289.9	\$4,953,608	\$7	-9.2%	-7.0%
Facility Outpatient Other	463.9	\$2,902,645	\$4	506.5	\$4,196,108	\$6	9.2%	42.2%
Facility Outpatient Pharmacy	487.0	\$1,379,447	\$2	520.3	\$2,967,933	\$4	6.9%	111.6%
Facility Outpatient PT, OT, Speech Therapy	1,100.6	\$2,576,138	\$4	993.6	\$2,567,666	\$3	-9.7%	-2.0%
Facility Outpatient Supplies and Devices	214.0	\$291,607	\$0	204.6	\$581,355	\$1	-4.4%	96.1%
Facility Outpatient Home Health	44.4	\$563,889	\$1	36.2	\$483,506	\$1	-18.4%	-15.7%
Facility Outpatient Transportation	10.7	\$270,180	\$0	10.5	\$325,350	\$0	-2.2%	18.4%
Facility Outpatient DME	1.8	\$51,447	\$0	1.9	\$47,283	\$0	3.9%	-9.6%

Laboratory Services

Lab Services	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Services per 1000	Net Pay Med	PEPM Med	Services per 1000	Net Pay Med	PEPM Med	Utilization	PEPM
Laboratory Outpatient Other	2,233.2	\$3,840,163	\$5	2,339.3	\$4,680,018	\$6	4.8%	19.9%
Laboratory Outpatient Chemistry Tests	2,919.7	\$3,830,853	\$5	2,942.0	\$4,655,703	\$6	0.8%	19.5%
Laboratory Outpatient Pathology	535.5	\$3,665,652	\$5	577.2	\$4,021,905	\$5	7.8%	7.9%

Mental Health and Substance Abuse

MH / SA Services	Utilization Type	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Mental Health Other Outpatient	Visits per 1000	796.9	\$7,547,687	\$10	827.8	\$7,027,922	\$10	3.9%	-8.4%
Mental Health Inpatient	Days Per 1000	38.5	\$3,341,600	\$5	38.8	\$3,341,428	\$5	1.0%	-1.7%
Substance Abuse Other Outpatient	Visits per 1000	44.1	\$2,804,855	\$4	77.6	\$2,126,368	\$3	76.0%	-25.4%
Substance Abuse Inpatient	Days Per 1000	24.9	\$1,953,187	\$3	15.9	\$1,611,812	\$2	-36.1%	-18.8%
Mental Health Office Visits	Visits per 1000	287.0	\$1,718,995	\$2	288.0	\$1,549,524	\$2	0.4%	-11.3%
Substance Abuse Office Visits	Visits per 1000	13.9	\$79,053	\$0	16.2	\$85,715	\$0	16.2%	6.6%

Non-Physician Professional Services

Non-Physician Professional Services	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Services / 1000	Net Pay Med	PEPM	Services / 1000	Net Pay Med	PEPM	Utilization	PEPM
Professional Specialty Drugs	273.5	\$20,071,084	\$28	265.4	\$18,958,881	\$26	-3.0%	-7.1%
Professional Services Other	594.3	\$11,481,928	\$16	595.6	\$10,280,243	\$14	0.2%	-11.9%
Professional PT, OT, Speech Therapy	4,192.1	\$6,947,614	\$10	4,505.8	\$7,577,711	\$10	7.5%	7.3%
Professional Diagnostic Services	1,348.2	\$5,880,116	\$8	1,467.7	\$6,463,222	\$9	8.9%	8.1%
Professional Office Visits	702.5	\$5,208,522	\$7	821.1	\$6,272,740	\$9	16.9%	18.4%
Professional Supplies and Devices	1,044.6	\$4,620,937	\$6	1,130.4	\$5,012,333	\$7	8.2%	6.7%
Professional DME	377.0	\$2,299,530	\$3	385.4	\$2,882,836	\$4	2.2%	23.3%
Professional Injections	788.0	\$2,560,894	\$4	730.3	\$2,813,316	\$4	-7.3%	8.0%
Professional Transportation	192.6	\$2,621,137	\$4	186.0	\$2,263,859	\$3	-3.4%	-15.1%
Professional Chiropractic Services	816.3	\$2,083,933	\$3	814.0	\$2,137,705	\$3	-0.3%	0.9%
Professional Home Health	78.7	\$1,127,342	\$2	177.3	\$1,356,850	\$2	125.4%	18.4%
Professional Dialysis	28.2	\$210,347	\$0	28.3	\$207,737	\$0	0.5%	-2.9%

Physician Inpatient Services

Physician Inpatient Services	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Services / 1000	Net Pay Med	PEPM	Services / 1000	Net Pay Med	PEPM	Utilization	PEPM
Physician Specialty Inpatient	966.4	\$11,858,852	\$16	894.3	\$11,467,066	\$16	-7%	-5%
Physician Non-Specialty Inpatient	614.0	\$4,672,264	\$6	594.3	\$4,586,977	\$6	-3%	-3%

Physician Outpatient

Physician Outpatient Service Category	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Visits / 1000	Net Pay Med	PEPM	Visits / 1000	Net Pay Med	PEPM	Utilization	PEPM
Physician Non-Specialty Office Visits	2,771.6	\$21,686,729	\$30	2,683.4	\$20,566,114	\$28	-3%	-7%
Physician Specialty Outpatient Surgery	428.8	\$18,632,680	\$26	394.5	\$17,465,971	\$24	-8%	-8%
Physician Specialty Office Visits	2,546.0	\$12,770,440	\$18	2,412.7	\$12,954,559	\$18	-5%	0%
Physician Specialty Outpatient Other	817.6	\$5,444,849	\$8	809.7	\$5,906,691	\$8	-1%	7%
Physician Specialty ER	330.1	\$3,889,878	\$5	320.1	\$4,705,985	\$6	-3%	19%
Physician Non-Specialty Outpatient Other	274.0	\$1,702,916	\$2	322.8	\$2,136,312	\$3	18%	23%
Physician Non-Specialty Outpatient Surgery	42.6	\$1,520,001	\$2	42.8	\$1,486,666	\$2	1%	-4%
Physician Non-Specialty ER	31.7	\$355,040	\$0	34.4	\$471,067	\$1	9%	30%

Radiology Services

Radiology Services	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Services/1000	Net Pay Med	PEPM	Services/1000	Net Pay Med	PEPM	Utilization	PEPM
Radiology Outpatient Therapeutic Radiology	203.00	\$6,181,810.48	\$8.55	213.60	\$9,466,401.69	\$12.87	5.2%	50.6%
Radiology Outpatient MRIs	161.16	\$4,368,265.96	\$6.04	154.98	\$4,766,714.52	\$6.48	-3.8%	7.3%
Radiology Outpatient Ultrasounds	417.67	\$4,227,564.16	\$5.85	404.59	\$4,472,014.48	\$6.08	-3.1%	4.0%
Radiology Outpatient CAT Scans	186.26	\$2,628,774.81	\$3.63	179.63	\$3,569,314.00	\$4.85	-3.6%	33.5%
Radiology Outpatient Mammograms	386.02	\$2,915,432.85	\$4.03	253.99	\$2,765,822.73	\$3.76	-34.2%	-6.7%
Radiology Outpatient X-Rays	796.96	\$2,052,207.75	\$2.84	766.00	\$2,434,736.79	\$3.31	-3.9%	16.7%
Radiology Outpatient Nuclear Medicine	75.13	\$1,715,719.17	\$2.37	73.06	\$1,706,910.63	\$2.32	-2.8%	-2.2%
Radiology Outpatient Other	58.88	\$1,289,482.71	\$1.78	55.76	\$1,400,082.72	\$1.90	-5.3%	6.8%

Place of Service by Net Payments and Utilization

Laboratories

Place of Service - Lab	Utilization Type	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Outpatient Hospital-On Campus	Visits per 1000	618.5	\$9,924,684	\$14	607.3	\$11,192,060	\$15	-1.8%	12.8%
Independent Laboratory	Visits per 1000	876.8	\$5,836,570	\$8	863.9	\$5,800,301	\$8	-1.5%	-0.6%
Ambulatory Surgical Center	Visits per 1000	8.2	\$165,272	\$0	7.8	\$113,231	\$0	-5.9%	-31.5%

Emergency Rooms & Urgent Care

Place of Service	Utilization Type	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Emergency Room (All Services)	Visits per 1000	378.5	\$43,909,649	\$61	379.8	\$49,448,352	\$67	0.4%	12.6%
Emergency Room (Urgent Care Services)	Visits per 1000	173.0	\$13,902,127	\$19	163.3	\$15,119,405	\$21	-5.6%	8.8%
Urgent Care Facility	Visits per 1000	454.9	\$4,344,127	\$6	470.3	\$4,864,178	\$7	3.4%	12.0%

Outpatient Hospital and Freestanding High-Tech Radiology

Place of Service	Utilization Type	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
		Utilization	Net Pay Med	PEPM	Utilization	Net Pay Med	PEPM	Utilization	PEPM
Outpatient Hospital	Visits per 1000	218.6	\$13,750,812	\$19	212.3	\$16,501,654	\$23	-2.9%	20.0%
Freestanding Facility	Visits per 1000	121.2	\$3,119,723	\$4	123.9	\$3,375,285	\$5	2.2%	8.2%

Top 20 Physician Specialties by Net Payments and Utilization

Provider Type	Jul 2016 - Jun 2017			Jul 2017 - Jun 2018			Trend	
	Services / 1000	Net Pay Med	PEPM	Services / 1000	Net Pay Med	PEPM	Utilization	PEPM
Family Practice	2,273.8	\$9,518,152	\$13	2,278.0	\$8,917,694	\$12	0.2%	-7.9%
Pediatrician (NEC)	1,302.0	\$8,599,504	\$12	1,440.3	\$8,643,409	\$12	10.6%	-1.1%
Orthopaedic Surgery	776.8	\$7,802,762	\$11	807.2	\$8,550,392	\$12	3.9%	7.8%
Obstetrics & Gynecology	685.7	\$8,948,954	\$12	649.8	\$8,248,144	\$11	-5.2%	-9.3%
Anesthesiology	351.3	\$8,075,945	\$11	319.9	\$8,054,104	\$11	-8.9%	-1.9%
Internal Medicine (NEC)	1,449.8	\$6,394,774	\$9	1,363.1	\$6,253,632	\$9	-6.0%	-3.8%
Radiology	1,394.5	\$6,609,396	\$9	1,212.9	\$6,244,805	\$8	-13.0%	-7.1%
Emergency Medicine	380.7	\$4,183,054	\$6	371.6	\$5,085,948	\$7	-2.4%	19.6%
Cardiovascular Dis/Cardiology	1,024.4	\$4,716,711	\$7	1,019.7	\$4,834,238	\$7	-0.5%	0.8%
Rheumatology	168.5	\$4,020,304	\$6	167.0	\$4,661,147	\$6	-0.9%	14.0%
Ophthalmology	611.8	\$4,472,159	\$6	600.5	\$4,650,475	\$6	-1.8%	2.3%
Oncology	296.3	\$5,195,437	\$7	245.6	\$4,244,217	\$6	-17.1%	-19.7%
Gastroenterology	257.0	\$3,760,632	\$5	228.2	\$3,461,850	\$5	-11.2%	-9.5%
Chiropractor/DCM	1,340.8	\$2,926,081	\$4	1,379.2	\$3,078,636	\$4	2.9%	3.5%
Dermatology	574.4	\$2,625,665	\$4	565.3	\$2,735,466	\$4	-1.6%	2.5%
Otolaryngology	294.3	\$2,848,165	\$4	278.2	\$2,601,750	\$4	-5.5%	-10.2%
Surgeon (NEC)	257.2	\$3,169,059	\$4	207.2	\$2,572,106	\$3	-19.4%	-20.2%
Neurology	192.0	\$1,933,801	\$3	177.0	\$2,068,555	\$3	-7.8%	5.2%
Urology	318.5	\$2,137,179	\$3	297.6	\$2,039,823	\$3	-6.6%	-6.1%
Plastic/Maxillofacial Surgery	120.0	\$1,789,467	\$2	135.9	\$2,017,554	\$3	13.2%	10.9%




Rx Net Pay, Utilization and Generic Efficiency

Mail/Retail by Days Supply, Generic Efficiency and Net Pay

	Jul 2016 – Jun 2017			Jul 2017 – Jun 2018			Trend		
	Days Supply Rx	Generic Efficiency	Net Pay PEPM Rx	Days Supply Rx	Generic Efficiency	Net Pay PEPM Rx	Days Supply Rx	Generic Efficiency	Net Pay PEPM Rx
Mail Order	9,628,609	90.1%	\$962	10,109,422	90.8%	\$1,137	5.0%	0.7%	18.2%
Retail	60,191,926	97.8%	\$2,456	60,585,619	96.9%	\$2,470	0.7%	-0.8%	0.6%
Total	69,820,535	97.2%	\$3,417	70,695,041	96.5%	\$3,607	1.3%	-0.8%	5.6%

Mail/Retail by Days Supply, Generic Efficiency and Net Pay

	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
	Net Pay Rx {Compl}	Days Supply	Net Pay Rx {Compl}	Days Supply	Net Pay	Days Supply
Generic	\$43,932,929	56,785,459	\$36,731,489	58,012,333	-16.4%	2.2%
Brand	\$86,139,682	9,925,493	\$91,393,773	9,219,989	6.1%	-7.1%
Specialty	\$69,452,884	1,082,653	\$86,063,034	1,206,444	23.9%	11.4%



High Cost Claimants (HCCs)

Service Category Group Net Pay and Utilization for HCCs

Service Category Group	Utilization Type	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
		Utilization	Net Pay Med	Utilization	Net Pay Med	Utilization	Net Pay
Facility Inpatient	Patients	439	49,816,101	487	52,365,011	10.9%	5.1%
Facility Outpatient	Patients	635	29,136,788	749	39,909,820	18.0%	37.0%
Other Professional Services	Patients	687	9,953,069	810	10,351,288	17.9%	4.0%
Radiology Outpatient	Patients	598	5,403,308	704	8,156,400	17.7%	51.0%
Physician Inpatient	Patients	466	4,860,359	521	4,897,473	11.8%	0.8%
Physician Outpatient	Patients	701	2,318,844	821	2,611,096	17.1%	12.6%
MHSA	Patients	200	2,397,835	223	1,735,087	11.5%	-27.6%
Laboratory Outpatient	Patients	655	908,670	757	1,231,926	15.6%	35.6%

Top Clinical Conditions Among High Cost Claimants

Jul 2016 - Jun 2017		Jul 2017 - Jun 2018	
Clinical Condition	Net Pay Med	Clinical Condition	Net Pay Med
Renal Function Failure	\$4,666,752	Chemotherapy Encounters	\$11,333,994
Chemotherapy Encounters	\$4,366,761	Coronary Artery Disease	\$4,662,877
Cardiac Arrhythmias	\$4,250,071	Renal Function Failure	\$4,273,640
Condition Rel to Tx - Med/Surg	\$4,038,302	Newborns, w/wo Complication	\$4,125,717
Infections, NEC	\$3,891,767	Multiple Sclerosis	\$3,641,112
Spinal/Back Disord, Low Back	\$3,465,751	Radiation Therapy Encounters	\$3,495,472
Cancer - Leukemia	\$3,393,767	Spinal/Back Disord, Low Back	\$3,424,863
Cerebrovascular Disease	\$3,183,825	Condition Rel to Tx - Med/Surg	\$3,365,073
Newborns, w/wo Complication	\$3,014,997	Signs/Symptoms/Oth Cond, NEC	\$3,275,702
Cancer - Breast	\$2,901,160	Cancer - Breast	\$3,056,975

High Cost Claimants – Top Therapeutic Classes

Therapeutic Class	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
	Net Pay Rx	Patients	Net Pay Rx	Patients	Net Pay	Utilization
Antineoplastic Agents	\$9,415,372	135	\$12,364,450	173	31.3%	28.1%
Misc Therapeutic Agents	\$4,478,286	172	\$6,210,433	186	38.7%	8.1%
Immunosuppressants	\$2,085,278	55	\$3,596,703	67	72.5%	21.8%
Cardiovascular Agents	\$1,728,019	479	\$2,316,943	559	34.1%	16.7%
Anti-Infective Agents	\$1,748,915	524	\$1,647,121	623	-5.8%	18.9%

DRAFT

APPENDIX

DRAFT

Top 50 Non-Specialty Drugs

Product	Therapeutic Class	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
HUMALOG KWIKPEN	Hormones & Synthetic Subst	\$3,857,510	208,232	\$4,307,605	196,218	11.7%	-5.8%
JANUVIA	Hormones & Synthetic Subst	\$3,592,187	319,429	\$4,072,683	299,961	13.4%	-6.1%
ELIQUIS	Blood Form/Coagul Agents	\$2,520,607	225,316	\$3,726,876	288,944	47.9%	28.2%
XARELTO	Blood Form/Coagul Agents	\$2,588,132	231,718	\$3,371,618	259,015	30.3%	11.8%
LANTUS SOLOSTAR PEN	Hormones & Synthetic Subst	\$2,744,113	291,077	\$2,775,993	257,707	1.2%	-11.5%
VYVANSE	Central Nervous System	\$2,240,813	283,868	\$2,528,476	293,857	12.8%	3.5%
HUMALOG	Hormones & Synthetic Subst	\$1,738,277	90,987	\$2,078,466	94,110	19.6%	3.4%
INVOKANA	Hormones & Synthetic Subst	\$2,058,064	167,572	\$1,915,903	132,464	-6.9%	-21.0%
METFORMIN HCL	Hormones & Synthetic Subst	\$2,480,043	1,664,188	\$1,882,259	1,704,727	-24.1%	2.4%
CONCERTA	Central Nervous System	\$5,733	550	\$1,724,357	133,424	29978.1%	24158.9%
OXYCONTIN	Central Nervous System	\$1,663,393	81,814	\$1,631,355	74,363	-1.9%	-9.1%
MYRBETRIQ	Smooth Muscle Relaxants	\$1,071,650	115,821	\$1,489,244	140,200	39.0%	21.0%
SYMBICORT 160/4.5	Hormones & Synthetic Subst	\$1,337,713	156,502	\$1,457,135	154,122	8.9%	-1.5%
ADDERALL XR	Central Nervous System	\$59,869	9,318	\$1,446,341	176,042	2315.8%	1789.3%
JARDIANCE	Hormones & Synthetic Subst	\$571,114	45,530	\$1,430,815	97,080	150.5%	113.2%
SPIRIVA	Autonomic Drugs	\$1,558,542	148,026	\$1,415,810	117,220	-9.2%	-20.8%
JANUMET	Hormones & Synthetic Subst	\$1,255,287	117,688	\$1,286,093	101,513	2.5%	-13.7%
ADVAIR DISKUS 250/50	Hormones & Synthetic Subst	\$1,248,208	120,928	\$1,231,543	103,415	-1.3%	-14.5%
LATUDA	Central Nervous System	\$797,286	22,425	\$1,126,363	27,700	41.3%	23.5%
EZETIMIBE	Cardiovascular Agents	\$1,035,236	141,506	\$1,124,235	337,003	8.6%	138.2%
ONE TOUCH ULTRA	Diagnostic Agents	\$1,279,905	375,169	\$1,112,197	328,586	-13.1%	-12.4%
ANDROGEL	Hormones & Synthetic Subst	\$950,700	41,725	\$1,062,989	39,615	11.8%	-5.1%
LEVEMIR FLEXTOUCH	Hormones & Synthetic Subst	\$1,177,160	102,782	\$1,044,076	79,400	-11.3%	-22.7%
HUMALOG MIX 75/25 KWIKPEN	Hormones & Synthetic Subst	\$943,396	39,081	\$1,035,396	36,023	9.8%	-7.8%
TOUJEO	Hormones & Synthetic Subst	\$932,931	70,936	\$979,793	65,237	5.0%	-8.0%
TRESIBA	Hormones & Synthetic Subst	\$591,093	37,690	\$970,395	59,501	64.2%	57.9%


Product	Therapeutic Class	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
BREO ELLIPTA	Hormones & Synthetic Subst	\$580,312	63,180	\$951,697	94,110	64.0%	49.0%
MOMETASONE FUROATE	Eye, Ear, Nose Throat	\$1,077,261	175,739	\$933,171	149,366	-13.4%	-15.0%
VESICARE	Smooth Muscle Relaxants	\$906,263	100,311	\$900,848	85,870	-0.6%	-14.4%
PRADAXA	Blood Form/Coagul Agents	\$993,468	92,814	\$861,764	71,998	-13.3%	-22.4%
MESALAMINE	Gastrointestinal Drugs	\$87,215	4,307	\$861,426	43,859	887.7%	918.3%
ESOMEPRAZOLE MAGNESIUM	Gastrointestinal Drugs	\$1,876,445	857,365	\$823,391	801,104	-56.1%	-6.6%
EZETIMIBE-SIMVASTATIN	Cardiovascular Agents	\$132,800	32,210	\$772,828	202,625	481.9%	529.1%
XIFAXAN	Anti-Infective Agents	\$689,392	10,700	\$769,571	10,308	11.6%	-3.7%
LO LOESTRIN FE	Hormones & Synthetic Subst	\$642,074	171,966	\$766,329	187,406	19.4%	9.0%
RESTASIS	Eye, Ear, Nose Throat	\$842,819	63,490	\$727,053	47,596	-13.7%	-25.0%
RANEXA	Cardiovascular Agents	\$659,322	56,130	\$717,399	53,251	8.8%	-5.1%
METOPROLOL SUCCINATE	Cardiovascular Agents	\$515,895	1,047,510	\$696,383	1,244,950	35.0%	18.8%
ROSUVASTATIN CALCIUM	Cardiovascular Agents	\$2,475,606	1,319,573	\$687,859	1,446,822	-72.2%	9.6%
BYSTOLIC	Cardiovascular Agents	\$604,401	179,921	\$661,166	177,487	9.4%	-1.4%
LIBRAX	Autonomic Drugs	\$283,473	2,850	\$652,521	4,845	130.2%	70.0%
LINZESS	Gastrointestinal Drugs	\$534,170	50,509	\$635,239	53,081	18.9%	5.1%
MULTAQ	Cardiovascular Agents	\$588,291	35,524	\$598,923	32,193	1.8%	-9.4%
BYDUREON PEN	Hormones & Synthetic Subst	\$457,347	23,149	\$573,273	24,924	25.3%	7.7%
JANUMET XR	Hormones & Synthetic Subst	\$461,392	44,732	\$573,098	48,212	24.2%	7.8%
LEVOTHYROXINE SODIUM	Hormones & Synthetic Subst	\$547,997	2,147,607	\$569,022	2,108,797	3.8%	-1.8%
CIALIS	Cardiovascular Agents	\$521,418	76,831	\$567,473	65,989	8.8%	-14.1%
PROAIR HFA	Autonomic Drugs	\$474,686	349,014	\$554,848	368,232	16.9%	5.5%
DEXILANT	Gastrointestinal Drugs	\$483,473	68,925	\$550,510	68,037	13.9%	-1.3%
LUMIGAN	Eye, Ear, Nose Throat	\$520,043	103,749	\$545,061	94,307	4.8%	-9.1%
BREO ELLIPTA	Hormones & Synthetic Subst	\$580,312	63,180	\$951,697	94,110	64.0%	49.0%

Top 50 Specialty Drugs


Product	Therapeutic Class	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
HUMIRA	Immunosuppressants	\$8,633,954	52,630	\$11,225,231	59,280	30.0%	12.6%
REVLIMID	Misc Therapeutic Agents	\$3,431,918	8,015	\$4,529,584	9,037	32.0%	12.8%
ENBREL	Immunosuppressants	\$3,983,554	26,327	\$4,266,031	25,906	7.1%	-1.6%
TRULICITY	Hormones & Synthetic Subst	\$2,310,676	112,171	\$4,152,339	171,547	79.7%	52.9%
STELARA	Immunosuppressants	\$1,442,929	6,350	\$2,608,125	10,926	80.8%	72.1%
GILENYA	Misc Therapeutic Agents	\$2,634,855	11,586	\$2,594,295	10,296	-1.5%	-11.1%
LYRICA	Central Nervous System	\$1,902,320	152,777	\$2,240,787	144,747	17.8%	-5.3%
IBRANCE	Antineoplastic Agents	\$1,423,865	3,563	\$2,238,460	5,334	57.2%	49.7%
VICTOZA	Hormones & Synthetic Subst	\$1,883,489	87,118	\$2,187,635	79,989	16.1%	-8.2%
HARVONI	Anti-Infective Agents	\$1,956,224	1,652	\$1,861,684	1,652	-4.8%	0.0%
TECFIDERA	Misc Therapeutic Agents	\$1,199,949	5,502	\$1,663,335	7,050	38.6%	28.1%
FORTEO	Misc Therapeutic Agents	\$916,777	9,744	\$1,387,548	12,076	51.4%	23.9%
COSENTYX	Immunosuppressants	\$600,370	3,248	\$1,312,625	6,923	118.6%	113.1%
OTEZLA	Misc Therapeutic Agents	\$769,862	8,398	\$1,305,637	12,750	69.6%	51.8%
SPRYCEL	Antineoplastic Agents	\$736,880	1,854	\$1,296,739	3,180	76.0%	71.5%
COPAXONE	Misc Therapeutic Agents	\$1,930,219	10,358	\$1,271,106	7,100	-34.1%	-31.5%
IMBRUVICA	Antineoplastic Agents	\$976,742	2,640	\$1,196,748	3,028	22.5%	14.7%
GENVOYA	Anti-Infective Agents	\$679,529	7,560	\$1,068,706	10,860	57.3%	43.7%
XTANDI	Antineoplastic Agents	\$853,877	2,700	\$1,056,244	2,982	23.7%	10.4%
XELJANZ XR	Immunosuppressants	\$230,844	1,860	\$1,040,535	7,710	350.8%	314.5%
XELJANZ	Immunosuppressants	\$877,317	7,152	\$873,610	6,630	-0.4%	-7.3%
TASIGNA	Antineoplastic Agents	\$748,119	2,014	\$825,957	1,944	10.4%	-3.5%
IMATINIB MESYLATE	Antineoplastic Agents	\$203,740	720	\$825,164	3,210	305.0%	345.8%
PROMACTA	Blood Form/Coagul Agents	\$263,400	870	\$821,162	1,560	211.8%	79.3%
ZYTIGA	Antineoplastic Agents	\$1,003,800	3,426	\$765,254	2,334	-23.8%	-31.9%
POMALYST	Antineoplastic Agents	\$688,502	1,211	\$744,335	1,393	8.1%	15.0%

Product	Therapeutic Class	Jul 2016 - Jun 2017		Jul 2017 - Jun 2018		Trend	
		Net Pay Rx	Days Supply	Net Pay Rx	Days Supply	Net Pay	Days Supply
CABOMETYX	Antineoplastic Agents	\$29,377	56	\$742,910	1,010	2428.9%	1703.6%
REPATHA	Cardiovascular Agents	\$234,369	5,172	\$732,823	16,974	212.7%	228.2%
OFEV	Antineoplastic Agents	\$533,537	1,470	\$725,403	2,310	36.0%	57.1%
SENSIPAR	Misc Therapeutic Agents	\$846,878	21,529	\$720,980	16,652	-14.9%	-22.7%
AVONEX PEN	Misc Therapeutic Agents	\$471,523	2,162	\$653,090	2,688	38.5%	24.3%
AUBAGIO	Immunosuppressants	\$505,537	2,436	\$644,216	2,856	27.4%	17.2%
LETAIRIS	Cardiovascular Agents	\$443,167	1,140	\$629,154	2,010	42.0%	76.3%
ESBRIET	Respiratory Tract Agents	\$366,324	1,170	\$609,217	2,130	66.3%	82.1%
AMPYRA	Central Nervous System	\$501,644	7,290	\$607,939	7,860	21.2%	7.8%
JAKAFI	Antineoplastic Agents	\$901,425	2,430	\$587,444	1,530	-34.8%	-37.0%
XOLAIR	Immunosuppressants	\$427,899	4,144	\$571,948	5,404	33.7%	30.4%
TRIUMEQ	Anti-Infective Agents	\$373,181	4,410	\$540,880	5,850	44.9%	32.7%
AFINITOR	Antineoplastic Agents	\$545,931	1,202	\$532,488	888	-2.5%	-26.1%
NORDITROPIN FLEXPPO	Hormones & Synthetic Subst	\$450,678	3,609	\$521,153	3,561	15.6%	-1.3%
VOTRIENT	Antineoplastic Agents	\$251,225	852	\$513,289	1,402	104.3%	64.6%
OPSUMIT	Cardiovascular Agents	\$491,733	1,350	\$492,748	1,650	0.2%	22.2%
ADEMPAS	Cardiovascular Agents	\$345,936	780	\$485,677	1,485	40.4%	90.4%
TRUVADA	Anti-Infective Agents	\$372,441	7,385	\$472,369	8,475	26.8%	14.8%
AVONEX	Misc Therapeutic Agents	\$537,598	2,520	\$447,543	1,960	-16.8%	-22.2%
ATRIPLA	Anti-Infective Agents	\$569,417	6,840	\$427,915	4,950	-24.9%	-27.6%
ALECENSA	Antineoplastic Agents	\$10,245	30	\$425,460	944	4052.9%	3046.7%
ORKAMBI	Respiratory Tract Agents	\$284,395	392	\$395,042	532	38.9%	35.7%
GAMUNEX-C	Serums, Toxoids, Vaccines	\$411,405	1,168	\$377,756	1,491	-8.2%	27.7%
ORENCIA PRE-FILLED SYRINGE	Immunosuppressants	\$427,743	2,952	\$374,775	2,420	-12.4%	-18.0%
CABOMETYX	Antineoplastic Agents	\$29,377	56	\$742,910	1,010	2428.9%	1703.6%

Top 5 Non-Specialty Products – 12 Month Trends



Top 5 Specialty Products – 12 Month Trends



DRAFT

Glossary

Days per 1000 Adm Acute - the average number of days from acute admissions per 1000 members with medical coverage per year.

Days Supply – is the number of days for which drugs were supplied for prescriptions filled.

Generic Efficiency – the number of prescriptions filled with a generic drug, expressed as a percentage of all prescriptions filled that could have been filled with a generic drug.

Svcs Per 1000 – the average number of services provided under medical coverage per 1000 members with medical coverage per year.

Visits per 1000 – the average number of outpatient facility visits under medical coverage, per 1000 members with medical coverage per year.

DRAFT